Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.
暂无分享,去创建一个
V. Gebski | I. Marschner | S. Loi | C. Geyer | D. Cameron | S. Johnston | J. Simes | M. Press | A. Di Leo | P. de Souza | S. Lord | L. Davies | C. Ellis | C. Lee
[1] S. Dawson,et al. Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] J. Baselga,et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] T. Fehm,et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. , 2014, The Lancet. Oncology.
[4] H. Gómez,et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Carlos Caldas,et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.
[6] J. Baselga,et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] H. Tesch,et al. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial , 2010, Breast Cancer Research and Treatment.
[8] J. Baselga,et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] W. Carney,et al. Value of serum human epidermal growth factor receptor 2 (HER2)/neu testing for early prediction of response to HER2/neu-directed therapies is still an open one and deserves further study in large prospective trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Arbushites,et al. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Saeed Sadeghi,et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. J. van de Vijver,et al. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] H. Gómez,et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] F. Esteva,et al. Serum HER‐2/neu and relative resistance to trastuzumab‐based therapy in patients with metastatic breast cancer , 2008, Cancer.
[15] M. Casey,et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses , 2008, Breast Cancer Research and Treatment.
[16] M. Berger,et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.
[17] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[18] Jinha M. Park,et al. Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials , 2005, Clinical Cancer Research.
[19] R. Neumann,et al. Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours. , 2005, Anticancer research.
[20] C. Hudis,et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] B. Jensen,et al. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] R. Molina,et al. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer. , 2003, Anticancer research.
[23] Jinha M. Park,et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] W. Wilmanns,et al. Clinical Relevance of Soluble c-erbB-2 for Patients with Metastatic Breast Cancer Predicting the Response to Second-Line Hormone or Chemotherapy , 2002, Tumor Biology.
[25] W. Sauerbrei,et al. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. , 1994, Journal of the National Cancer Institute.
[26] O. Kallioniemi,et al. Elevated erbB‐2 oncoprotein levels in preoperative and follow‐up serum samples define an aggressive disease course in patients with breast cancer , 1994, Cancer.
[27] C. Kotts,et al. ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. , 1990, Journal of immunological methods.